All participants in this study will receive azacitidine and venetoclax.~This study will be done in multiple stages:~Safety Run-In Period - 7 participants will receive the study drugs to ensure that the combination is safe and tolerable.~Stage 1 - About 15 participants will receive the study drugs and will be evaluated to see whether they respond to the study drugs.~Stage 2 - If enough participants in Stage 1 respond to the study drugs, then Stage 2 will begin. During this stage, an additional 25 participants will take part in the study to further see if participants respond to the study drugs.
The purpose of this research study is to look at how safe and useful a drug called azacitidine in combination with a drug called venetoclax, is in people with accelerated or blast phase BRC-ABL negative myeloproliferative neoplasms.